Abstract
To the Editor: Two years ago, we reported that the incorporation of thalidomide into high-dose therapy for myeloma increased the frequency of complete remission but not the duration of remission and extended event-free survival but not overall survival.1 We now report that after a median follow-up of 8 years, 399 patients remain alive and 286 are event-free, for median durations of 9 years and 5 years, respectively. Although the overall difference in the 8-year survival estimates of 56% for 323 patients who were randomly assigned to the thalidomide group and 45% for 345 patients in the control group was not . . .
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
